secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001171843-24-000112
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst announces FY2023 ORLADEYO revenue $325M (+29%), 2024 guidance $380-400M, sees operating profit in 2024
--------------------------------------------------------------------------------

- Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).
- 2024 ORLADEYO revenue guidance $380-400M; company reaffirms peak sales target of $1B.
- 2024 operating expenses expected flat at $365-375M; R&D reduced $20M vs 2023.
- Restructuring reduces workforce by 59 jobs (10%); plans to out-license BCX10013 if data supports.
- ORLADEYO WAC increased ~5% to $42,366 per 28-day pack, effective January 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/0001171843-24-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/f8k_010824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer